Janssen Biotech Inc. and Yuhan Corp. have synthesized substituted aminopyridine compounds acting as EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Researchers at Hangzhou Glubio Therapeutics Co. Ltd. have patented isoindolinone molecular glue degraders that induce DNA-binding protein Ikaros (IKZF1) degradation and are reported to be useful for the treatment of cancer.
A Katholieke Universiteit Leuven patent details 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues that act as viral replication inhibitors potentially useful for the treatment of viral infections.
Redx Pharma plc has described henyl- and pyridopyrazole derivatives as discoidin domain-containing receptor DDR1 and/or DDR2 inhibitors. They are reported to be useful for the treatment of fibrosis, cancer, transplant rejection, inflammatory, renal, liver and cardiovascular disorders.
Suzhou Genhouse Bio Co. Ltd. has prepared and tested new histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, asthma, Alzheimer’s diseases, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.